Access Official Technical PDF

Share Summary:LinkedInEmail

Automated hematology analyzer design is drawing on imaging and software as well as conventional instrument engineering. Sight OLO, a system cleared through the FDA’s 510(k) pathway in 2019, uses computer-vision algorithms to analyze stained blood samples and report complete blood count (CBC) parameters. For laboratory and automation leaders, its design offers a useful example of how sample handling, image analysis, consumables and quality controls come together in an in vitro diagnostic workflow.

The system is intended for use in clinical laboratories with capillary or venous whole blood. Its regulatory indications specify K2EDTA blood collection tubes or fingertip samples collected with the Sight OLO test-kit micro-capillary tubes. The FDA’s substantial-equivalence determination applies to the stated indications for use; it is not a determination that the device meets every other regulatory requirement.

How the automated hematology analyzer processes samples

Sight OLO consists of a scanning and analysis instrument and a test kit. The kit includes disposable cartridges and sample-preparation components. After the sample is prepared and loaded into the cartridge, the cartridge is inserted into the analyzer, which is operated through a touchscreen interface. The system automates the subsequent processing and analysis steps.

At the core of the measurement approach are dedicated staining, a fluorescence microscope and computer-vision algorithms. The analyzer captures images and software classifies blood components using visual characteristics such as cell size, shape, intensity and morphology. Hemoglobin is measured using optical density. This differs from the predicate Sysmex XN-Series analyzer, which uses methods including direct-current detection, flow cytometry and sodium lauryl sulfate hemoglobin measurement.

The reported CBC parameters include white blood cell (WBC) and red blood cell (RBC) counts, hemoglobin, hematocrit, red-cell indices, platelets and a five-part white blood cell differential: neutrophils, lymphocytes, monocytes, eosinophils and basophils. The submission also describes flags for specific abnormal WBC cases. A flag is a signal for attention, not a substitute for the laboratory’s established review and interpretation procedures.

Sample types, workflow and operating considerations

The stated use covers venous and capillary whole blood, including fingertip collection using the test-kit micro-capillary tubes. In comparative testing, the submission reported comparable performance for capillary and venous specimens, and for capillary samples collected in an EDTA microtube versus the specified fingertip collection method. These findings support the stated sample options, but laboratories still need to follow the device instructions and their own validated procedures.

The FDA submission describes the analyzer as factory calibrated, with no further calibration required by the user. Quality-control materials are available to monitor analyzer performance. This distinction matters in workflow planning: factory calibration does not remove the need for ongoing quality control, documented procedures or appropriate operator training. The disposable cartridge and sample-preparation materials are also part of the measurement system, so kit handling and storage belong in the laboratory’s process controls.

Sample stability is another practical factor. The submitted stability data support room-temperature use for up to eight hours after collection for the reported measurands, with RDW identified as an exception at four hours. These limits make collection time and specimen handling relevant to result quality and should be reflected in laboratory procedures.

What the performance evidence covers

The 510(k) submission describes method-comparison work at three U.S. sites using 679 residual clinical K2EDTA whole-blood samples, including adult and pediatric samples. Sight OLO results were compared with the Sysmex XN predicate. The study included normal and pathological samples across the analytical measuring range and around medical decision points. The submission reports that the measurands met predefined acceptance criteria for correlation, bias, slope and intercept.

Additional studies addressed repeatability, reproducibility, detection limits, linearity, interference, specimen stability and flagging. Precision testing involved multiple sites and assessed sources of variation including runs, days, instruments and sites. Flagging performance was compared with manual microscopy for normal and abnormal samples; the reported overall sensitivity was 93.0%, specificity 80.6% and agreement 86.5%. These figures describe the particular study and its criteria, rather than a guarantee of performance in every laboratory or specimen population.

For technical decision-makers, the broader lesson is to assess the evidence by workflow and use case. Relevant questions include whether the intended sample types match local collection practices, how quality control is implemented, what happens when a sample is flagged, and whether the reported parameters align with laboratory requirements. Regulatory status, analytical validation and operational suitability are related considerations, but they are not interchangeable.

Understanding the FDA 510(k) determination

In November 2019, the FDA determined Sight OLO substantially equivalent to legally marketed predicate devices for its stated indications. This 510(k) decision allows marketing subject to applicable general controls; it is not the same as premarket approval. The FDA letter also emphasizes that substantial equivalence does not establish compliance with every requirement of the Federal Food, Drug, and Cosmetic Act or other applicable regulations.

Manufacturers remain responsible for relevant obligations, including registration and listing, labeling, medical device reporting and quality-system requirements. For laboratories, the practical takeaway is to distinguish a device’s regulatory pathway from its suitability for a specific operating environment and the controls needed for safe, consistent use.

Conclusion

Sight OLO illustrates a diagnostic workflow in which image-based cell classification is integrated with sample preparation, disposable consumables and automated analysis. Its FDA 510(k) determination and submitted performance studies provide context for evaluating the system, while its stated specimen limits, quality-control approach and abnormal-sample flags remain important operational details. Laboratories considering automated CBC analysis should align device capabilities and validation evidence with their own procedures, staffing and quality requirements.

Access Official Technical PDF

About The Author